Search results
Results from the WOW.Com Content Network
Transgender, nonbinary, and intersex people are underserved by current contraceptive options. For example, many trans men can become pregnant (both intentionally and unintentionally), [226] but may prefer not to use estrogen- or progestin-containing hormonal birth control (both because of the social classification of these hormones as "female ...
The effects of hormonal birth control on breast cancer risk have been studied for decades. Many studies over the years have shown that hormone-containing birth control options, specifically ...
[48] [51] [49] About 5 to 10% of women experience negative mood changes with combined birth control pills, and about 5% of women discontinue birth control pills due to such changes. [ 52 ] [ 48 ] A study of about 4,000 women found that progestogen-only birth control with depot medroxyprogesterone acetate had an incidence of depression of 1.5% ...
They concluded that: "Overall, there was no evidence of an increased risk of breast cancer". [53] Recent anxieties about the contribution of progestogens to the increased risk of breast cancer associated with HRT in postmenopausal women such as found in the WHI trials [54] have not spread to progestogen-only contraceptive use in premenopausal ...
For premium support please call: 800-290-4726 more ways to reach us
Cyproterone acetate (CPA), sold alone under the brand name Androcur or with ethinylestradiol under the brand names Diane or Diane-35 among others, is an antiandrogen and progestin medication used in the treatment of androgen-dependent conditions such as acne, excessive body hair growth, early puberty, and prostate cancer, as a component of feminizing hormone therapy for transgender individuals ...
Studies have suggested for decades that birth control pills containing both estrogen and progestogen — synthetic versions of female hormones — may slightly elevate one’s risk of breast cancer.
A 2013 meta-analysis concluded that every use of birth control pills is associated with a modest increase in the risk of breast cancer (relative risk 1.08) and a reduced risk of colorectal cancer (relative risk 0.86) and endometrial cancer (relative risk 0.57).